NCT04094610
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations treatment 1 / 2 recruiting NCT06031441
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors treatment 1 recruiting NCT02045602
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors treatment 1 completed NCT03093116
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements treatment 1 / 2 recruiting NCT03427320
Imaging of Advanced Tumours Using [131]I-IAZA No drug interventions other 1 / 2 withdrawn NCT03646071
A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 1 unknown_status NCT03573544
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. treatment 1 / 2 terminated NCT02097810
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. treatment 1 completed NCT03059823
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors treatment 1 completed NCT06658353
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors No drug interventions treatment 3 not_yet_recruiting NCT04799054
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors treatment 1 / 2 active_not_recruiting NCT04975958
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors treatment 1 active_not_recruiting NCT05732831
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT06521554
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) No drug interventions treatment 1 recruiting NCT04084366
Phase 1/2 Study of OBI-999 in Patients with Advanced Solid Tumors treatment 1 / 2 terminated NCT05081609
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies treatment 1 / 2 recruiting NCT05731271
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors No drug interventions treatment 1 / 2 active_not_recruiting NCT06630247
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT05275478
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors treatment 1 / 2 recruiting NCT05169437
Niraparib in the Treatment of Patients with Advanced PALB2 Mutated Tumors treatment 2 terminated NCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers treatment 1 / 2 recruiting NCT05828277
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients treatment 1 withdrawn NCT03881488
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies treatment 1 active_not_recruiting NCT06416007
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors No drug interventions treatment 2 recruiting NCT05919537
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation treatment 1 recruiting NCT05769075
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations No drug interventions treatment 1 recruiting NCT01390818
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors treatment 1 completed NCT04914117
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours treatment 1 completed NCT06184035
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer treatment 1 / 2 recruiting NCT05378425
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab treatment 1 recruiting NCT04250948
Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer treatment 2 active_not_recruiting NCT05384626
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) treatment 1 / 2 recruiting NCT05268666
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors treatment 1 / 2 recruiting NCT05118789
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) No drug interventions treatment 1 / 2 recruiting NCT05002140
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients No drug interventions treatment 1 completed NCT04614740
The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT04814667
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib No drug interventions Not Available Not Available active_not_recruiting NCT04383210
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors treatment 2 active_not_recruiting NCT06349408
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 1 / 2 not_yet_recruiting NCT06534190
CD8 PET Imaging in Metastatic Solid Tumours treatment 2 not_yet_recruiting NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT03284502
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors treatment 1 active_not_recruiting NCT06415487
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) treatment 1 not_yet_recruiting NCT05028478
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies No drug interventions treatment 1 / 2 unknown_status NCT04770688
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib treatment 1 / 2 completed NCT04050709
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers treatment 1 active_not_recruiting NCT06028724
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) No drug interventions Not Available Not Available recruiting NCT04200963
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma treatment 1 completed NCT05717348
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours No drug interventions treatment 1 recruiting NCT05218148
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma treatment 2 not_yet_recruiting NCT04319757
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors treatment 1 recruiting NCT03428802
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability treatment 2 recruiting NCT03590054
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies treatment 1 completed